This was indicated in a study by Le et al., which was performed to evaluate the efficacy of the PD-1 blockade across 12 different tumor types, with MSI-H and dMMR, which were found to be sensitive to immune checkpoint blockade [76]. The gene discussed is PDCD1; the disease is neoplasm.